Please use this identifier to cite or link to this item:
|Title:||Distinct behaviour of sorafenib in experimental tumours inducing cachexia: the role of STATS3.|
|Author:||Toledo Soler, Miriam|
Busquets Rius, Sílvia
López-Soriano, Francisco J.
Argilés Huguet, Josep Ma.
|Publisher:||Public Library of Science (PLoS)|
|Abstract:||The presence of a tumour is very often associated with wasting in the host, affecting both skeletal muscle and adipose tissue. In the present study we used sorafenib, a multi-kinase inhibitor with anti-tumour activity, in order to investigate the effects of chemotherapy on wasting. Three different experimental mouse tumour models were included: C26 colon carcinoma, B16 melanoma and Lewis lung carcinoma (LLC). The results obtained clearly show that sorafenib was effective in reducing tumour growth in LLC and B16 models, while it had no effect on C26. Interestingly, sorafenib treatment reduced the signs of muscle wasting and improved the physical activity in the LLC model and also in the C26, despite the absence of antineoplastic action in the latter. Our results discard a role for IL-6 in the action of sorafenib since the drug did not affect the levels of this cytokine. Conversely, sorafenib seems to act by influencing both STAT3 and ERK activity at muscle level, leading to reduced accumulation of Pax7 and atrogin-1. Sorafenib may interfere with muscle wasting by decreasing the activation of these signal transduction pathways.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0113931|
|It is part of:||PLoS One, 2014, vol. 9, num. 12, p. 1-16|
|Appears in Collections:||Articles publicats en revistes (Bioquímica i Biomedicina Molecular)|
This item is licensed under a Creative Commons License